Sarepta Therapeutics
SRPT
254 hedge funds and large institutions have $3.03B invested in Sarepta Therapeutics in 2017 Q4 according to their latest regulatory filings, with 56 funds opening new positions, 78 increasing their positions, 91 reducing their positions, and 31 closing their positions.
81% more first-time investments, than exits
New positions opened: 56 | Existing positions closed: 31
24% more capital invested
Capital invested by funds: $2.44B → $3.03B (+$593M)
13% more call options, than puts
Call options by funds: $325M | Put options by funds: $287M
9% more funds holding
Funds holding: 233 → 254 (+21)
1.94% more ownership
Funds ownership: 83.52% → 85.46% (+1.9%)
14% less repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 91
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$184M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$57.6M |
| 3 |
Morgan Stanley
New York
|
+$30M |
| 4 |
PP
PDT Partners
New York
|
+$30M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
+$25.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$84M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$58.3M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$56.4M |
| 4 |
TCP
Tourbillon Capital Partners
New York
|
-$32M |
| 5 |
State Street
Boston,
Massachusetts
|
-$29.1M |
SRPT Hedge Fund Activity: Q4 2017 in Review
254 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q4 2017, worth a combined $3.03B — up 24% from $2.44B a quarter earlier.
Buyers outnumbered sellers: 56 funds opened new SRPT positions and 31 closed out — a net gain of 25 holders — while 78 added to existing stakes and 91 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $184M. The largest seller was Citadel Advisors, cutting an estimated $84M.
- 254 institutional investors held Sarepta Therapeutics (SRPT) as of Q4 2017, up from 233 in Q3 2017.
- Funds reported $3.03B of Sarepta Therapeutics stock for Q4 2017, up 24% quarter-over-quarter.
- 56 funds opened new Sarepta Therapeutics positions in Q4 2017 and 31 closed out, a net change of +25 holders.
- The largest Sarepta Therapeutics buyer in Q4 2017 was Fidelity Investments, an estimated $184M added.
- The largest Sarepta Therapeutics seller in Q4 2017 was Citadel Advisors, an estimated $84M sold.
Based on aggregated 13F filings for Q4 2017.